Leila Alland

Leila Alland, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in PMV Pharmaceuticals, Inc. and Abeona Therapeutics Inc. We count 33 filings; the first trade dates from 7 April 2021 and the latest from 30 June 2026.

Market trades split into 1 purchase (€48k) and 17 sales (€882k). Netting one side against the other leaves €834k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 8 share grants and 7 option exercises. So far in 2026, the count stands at no purchases and 2 sales.

On 2 July 2026 came the latest disclosure, an open-market sale for €57k in Abeona Therapeutics Inc. The most recent open-market purchase was published on 20 May 2024, 887 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.